Merck: This Cancer-Drug Powerhouse Could Be a Core Dividend
A dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
Conduct a value comparison of no annual fee cash back cards to find the right one for your spending needs. Make informed choices.
25,387 articlesA dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
For decades, a handful of dividend stocks have quietly grown wealth through reliable payouts and strategic resilience...
Piper Sandler trimmed its Upstart price target to $46 after a softer Q1 EBITDA print, but kept an Overweight rating a...
A single, six-word Fed statement could reshape how investors price risk. This analysis explores the potential impact,...
When a tech insider sells a large stake, investors weigh a range of signals. This guide breaks down what the move cou...
SK Hynix plans a $29 billion U.S. listing to capitalize on AI memory chip demand, highlighting a push to broaden inve...
Citigroup is up about 14% year-to-date through mid-July 2026, outpacing Bank of America and Wells Fargo. AI-driven tr...
Willamette Valley Bank will stop originating residential mortgages by March 31, citing stiff competition and a prolon...
Fintech down this year has pressured growth equities, yet cybersecurity ETFs are delivering relative steadiness as co...
Finance of America reported a profitable first quarter, reversing Q4 losses as originations climbed and portfolio gai...
As 2026 unfolds, smart glasses are poised for a pivotal year, led by Meta and Google. Apple sits on the sidelines wit...
As a global health scare rises in prominence, investors quiz whether bitcoin can withstand another black swan shock. ...